Cancer treatment through RLIP76 partial depletion
Partial depletion of RLIP76 in p53 deficient living subject has shown many health benefits. In one embodiment, partical Rlip depletion is used to prevent or treat cancer in p53 deficient living subjects. In another embodiment, partial Rlip depletion is used for reversion of DNA-methylation abnormalities caused by the lack of p53 to normal in p53 deficient living subjects. In yet another embodiment, partial Rlip depletion is used in reduction of blood glucose, insulin-resistance, hyperlipidemina, or any combination thereof in p53 deficient living subjects. Methods of using liposome containing anti-sense nucleic acid or double stranded siRNA to partially deplete RLIP76 and thus treat p53 deficient subject are disclosed. The approaches described herein can be especially helpful in preventing cancer in Li-Fraumeni patients.
1 . A method of treating a p53-null tumor in a subject, the method comprising administering an effective amount of a composition comprising a liposome inhibitory RNA molecule that inhibits RLIP76 into the subject, and inhibiting at least 25% of the total RLIP76 in the p53-null tumor.
2 . The method of claim 1 , wherein the liposome inhibitory RNA molecule is:
an anti-sense molecule having a nucleic acid sequence of SEQ ID NO.: 2;
an siRNA molecule comprised of SEQ ID NO: 3 and SEQ ID NO: 6; or
an anti-sense molecule complementary to an mRNA that encodes SEQ ID NO.: 4, and
wherein the inhibitory RNA molecule targets nucleotides encoding a region of RLIP76 having a sequence of SEQ ID NO.: 1.
3 . The method of claim 1 , wherein the effective amount comprises a dose of 0.1-30 mg/kg of the subject.
4 . The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
5 . The method of claim 1 , further comprising repeatedly administering the effective amount of the composition at predetermined intervals for chronically inhibiting at least 25% of the total RLIP76 in the p53-null tumor and chronically sustaining cancer treatment.
6 . The method of claim 1 , further comprising administering the effective amount of the composition for at least one year for measurably decreasing cancer in the subject.